Key result
Skeletal muscle cardiac assistance remains a principal investigational method for treating irreversible heart failure.
Skeletal muscle cardiac assistance, such as cardiomyoplasty, is discussed as an alternative approach for patients with irreversible heart failure.
Should not yet change practice in end-stage HF; leaves open comparative efficacy of skeletal muscle assistance versus transplantation or devices.
During the last several years, there has been intense worldwide interest concerning the use of skeletal muscle as a form of cardiac assistance. For over 10,000 people in the United States diagnosed each year with irreversible heart failure, the 1-year mortality approaches 50%. This comes despite recent advances in medical therapy, heart transplantation, and the artificial heart program. Because of the limitations of these treatments in terms of effectiveness, cost, and availability, we have used a different approach for cardiac augmentation. Skeletal muscle is shaped into the form of a pumping chamber and then used to aid the function of the failing myocardium. Another approach is cardiomyoplasty, where the latissimus dorsi muscle is wrapped around the heart and stimulated to contract in synchrony with the patient's failing myocardium. More than 500 patients have undergone cardiomyoplasty worldwide. These two areas of investigation represent the principle methods for skeletal muscle cardiac assistance.
No takes yet. Share an insight, caveat, or question.
Greer et al. (1996) conducted a review in Irreversible heart failure. Skeletal muscle cardiac assistance (cardiomyoplasty and skeletal muscle pumping chambers) was evaluated. Skeletal muscle cardiac assistance, including cardiomyoplasty and skeletal muscle pumping chambers, represents a principal method under investigation for treating irreversible heart failure.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: